“ULTRASOUND-RESPONSIVEPLGANANOBUBBLESFORIMPROVEDORAL BIOAVAILABILITY OF ENZALUTAMIDE: FORMULATION OPTIMIZATION AND PHARMACOKINETIC EVALUATION”

Read full text Summarise with VIRAT
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Poor aqueous solubility and low oral bioavailability limit the therapeutic effectiveness of enzalutamide, a second-generation androgen receptor inhibitor used in advanced prostate cancer. This study aimed to develop and optimize ultrasound-responsive PLGA nanobubbles to enhance oraldelivery andpharmacokinetic performance. Nanobubbles werepreparedusing thesolventevaporationmethodandoptimizedviaaBox–Behnkendesign,evaluating the effect of formulation variables on key quality attributes. The optimized formulation exhibited a particlesizeof193.5 ±2.8 nm, polydispersity index of 0.26± 0.016,zetapotential of−31.4± 1.17 mV, and entrapment efficiency of 65.12 ± 2.54%. Characterization by FTIR, DSC, and XRD confirmed drug–polymer compatibility, and SEM revealed uniform spherical morphology. In vitro studies showed sustained and ultrasound-triggered drug release. In vivo evaluationinWistarratsdemonstratedsignificantincreasesinC_maxandAUC₀–t,confirming enhanced oral absorption and prolonged systemic exposure. These results indicate that ultrasound-responsive PLGA nanobubbles are a promising oral delivery platform for poorly soluble anticancer drugs.

Fields of Study & Subjects

Drug Solubulity and Delivery Systems Advanced Drug Delivery Systems Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Journal of Bio Innovation
Volume
15
Issue
1
Pages
205–233
Publication date
30 January 2026
Language
EN